United Therapeutics makes ‘100 Best Companies to Work For’ list in 2025

United Therapeutics is a renowned biotechnology company committed to developing innovative solutions to improve the lives of patients with severe pulmonary arterial hypertension (PAH) and other life-threatening conditions. Founded by Dr. Martine Rothblatt, the company has a rich history of pioneering work in the field of biomedical research, with a primary focus on providing groundbreaking therapies for those in need. With locations and subsidiaries across the globe, United Therapeutics is dedicated to advancing the frontiers of science and medicine to address unmet medical needs.

One of United Therapeutics’ key areas of focus is developing advanced therapeutic treatments for patients suffering from end-stage lung diseases. The company offers a comprehensive range of medicines, including Remodulin, Tyvaso, Orenitram, Adcirca, and Unituxin, designed to provide relief and improve the quality of life for individuals dealing with these debilitating conditions. These medications play a critical role in managing symptoms, slowing disease progression, and enhancing overall well-being for patients living with severe lung diseases.

In addition to its line of medicines, United Therapeutics provides a unique service known as the LBE 360° Transplant Support Service, which offers invaluable assistance to patients navigating the complexities of organ transplantation. This service is designed to support patients and their families throughout the transplant process, providing education, resources, and guidance to ensure a smooth and successful transition before, during, and after the transplantation procedure.

United Therapeutics is at the forefront of scientific innovation, with a dedicated team of researchers and clinicians working tirelessly to advance the field of biomedicine. The company’s commitment to excellence is reflected in its robust pipeline of ongoing clinical trials, aimed at evaluating the safety and efficacy of promising new therapies for a wide range of medical conditions. Through its scientific library and extensive network of research partners, United Therapeutics continues to push the boundaries of what is possible in the realm of medical discovery.

For medical professionals seeking the latest information and resources in the field of pulmonary hypertension and related cardiovascular disorders, United Therapeutics’ Science and Medical Affairs division offers a wealth of knowledge and expertise. With a focus on advancing scientific understanding and promoting best practices in patient care, this division serves as a valuable resource for healthcare providers looking to enhance their clinical acumen and stay abreast of the latest developments in the field.

In conclusion, United Therapeutics stands as a beacon of hope for patients facing the challenges of severe pulmonary arterial hypertension and other life-threatening diseases. With a strong emphasis on corporate responsibility, innovation, and patient care, the company continues to make significant strides in advancing the frontiers of science and medicine. Through its unwavering commitment to improving the lives of those in need, United Therapeutics remains a leader in the biotechnology industry and a champion for patients around the world.